Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helena R. Chang

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Cancer|June 22, 2010
Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancerHelena R Chang
Cancer|February 17, 2001
Author replyRobert G. Parker, Helena R. Chang
International Journal of Molecular Medicine|January 14, 2005
In silico identification of breast cancer genes by combined multiple high throughput analysesDejun Shen, Jianbo He, Helena R Chang
Carcinogenesis|June 14, 2018
Integrated multiomic predictors for ovarian cancer survivalAlan Fu, Helena R Chang, Zuo-Feng Zhang
Breast Cancer : Basic and Clinical Research|August 25, 2011
Management options in triple-negative breast cancerChristina A Minami, Debra U Chung, Helena R Chang
Breast (Edinburgh, Scotland)|August 13, 2005
Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?Chandra N Burge, Helena R Chang, Sophia K Apple
The Breast Journal|May 20, 2003
Clinicopathologic analysis of sentinel lymph node mapping in early breast cancerSeung-Hye Choi, Sanford H Barsky, Helena R Chang
International Journal of Oncology|May 16, 2002
Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2Jianbo He, Dejun Shen, Michael A O'Donnell, et al.
Annals of Diagnostic Pathology|July 20, 2010
Heterotopic breast tissue versus occult metastatic carcinoma in lymph node, a diagnostic dilemmaSteven J Ohsie, Neda A Moatamed, Helena R Chang, et al.
The Breast Journal|November 22, 2005
Histopathologic characteristics predicting HER-2/neu amplification in breast cancerRaquel Prati, Sophia K Apple, Jianbo He, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Cancer|June 22, 2010
Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancerHelena R Chang
Cancer|February 17, 2001
Author replyRobert G. Parker, Helena R. Chang
International Journal of Molecular Medicine|January 14, 2005
In silico identification of breast cancer genes by combined multiple high throughput analysesDejun Shen, Jianbo He, Helena R Chang
Carcinogenesis|June 14, 2018
Integrated multiomic predictors for ovarian cancer survivalAlan Fu, Helena R Chang, Zuo-Feng Zhang
Breast Cancer : Basic and Clinical Research|August 25, 2011
Management options in triple-negative breast cancerChristina A Minami, Debra U Chung, Helena R Chang
Breast (Edinburgh, Scotland)|August 13, 2005
Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?Chandra N Burge, Helena R Chang, Sophia K Apple
The Breast Journal|May 20, 2003
Clinicopathologic analysis of sentinel lymph node mapping in early breast cancerSeung-Hye Choi, Sanford H Barsky, Helena R Chang
International Journal of Oncology|May 16, 2002
Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2Jianbo He, Dejun Shen, Michael A O'Donnell, et al.
Annals of Diagnostic Pathology|July 20, 2010
Heterotopic breast tissue versus occult metastatic carcinoma in lymph node, a diagnostic dilemmaSteven J Ohsie, Neda A Moatamed, Helena R Chang, et al.
The Breast Journal|November 22, 2005
Histopathologic characteristics predicting HER-2/neu amplification in breast cancerRaquel Prati, Sophia K Apple, Jianbo He, et al.
Pageof 4